Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Accumulated Expenses (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Accumulated Expenses for 11 consecutive years, with $26.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 26.01% year-over-year to $26.6 million, compared with a TTM value of $26.6 million through Dec 2025, up 26.01%, and an annual FY2025 reading of $26.6 million, up 26.01% over the prior year.
  • Accumulated Expenses was $26.6 million for Q4 2025 at Wave Life Sciences, up from $757000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $26.6 million in Q4 2025 and bottomed at $476000.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $6.1 million, with a median of $3.3 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses plummeted 92.85% in 2022, then soared 2018.69% in 2024.
  • Year by year, Accumulated Expenses stood at $1.1 million in 2021, then skyrocketed by 57.71% to $1.7 million in 2022, then plummeted by 43.11% to $995000.0 in 2023, then skyrocketed by 2018.69% to $21.1 million in 2024, then increased by 26.01% to $26.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for WVE at $26.6 million in Q4 2025, $757000.0 in Q3 2025, and $1.0 million in Q2 2025.